The GeneConvene Global Collaborative supports informed decision making on the unresolved scientific, regulatory, and policy questions raised by the potential for genetically modify mosquitoes to eliminate malaria, which sickens more than 200 million people globally each year. The program identifies key questions and convenes stakeholders to address them, creates and shares informative resources, and provides training on the rigorous evaluation of these technologies.​

Pathway to Impact
In 2023, GeneConvene members published the following:

• An article in a special collection volume (organized by GeneConvene Global Collaborative) of Transgenic Research focusing on the regulatory requirements for implementing gene drive technologies in national or regional public health programs.
• An article in Frontiers in Bioengineering and Biotechnology considering the approval procedures and market entry strategies for implementing gene drive-modified mosquitoes.
• An assessment by a neutral third party, CSIRO, of risks associated with the release of genetically modified mosquitoes by the Target Malaria project.
• A multi-country study in Malaria Journal exploring the insights and recommendations of key stakeholders across Africa on the potential of gene drive-modified mosquitoes for malaria control and elimination.

Members also:

• Supported training activities on operationalization of biosafety oversight and genetically modified organism decision making processes at African institutions.
• Advised the United Nations Convention on Biological Diversity on developing guidance for risk assessment of engineered gene drive-modified mosquitoes.